Hemostemix Inc. (CVE:HEM – Get Free Report) shares traded up 16.7% during mid-day trading on Wednesday . The stock traded as high as C$0.11 and last traded at C$0.11. 282,130 shares traded hands during trading, an increase of 296% from the average session volume of 71,223 shares. The stock had previously closed at C$0.09.
Hemostemix Price Performance
The stock has a market capitalization of C$5.66 million, a P/E ratio of -3.50 and a beta of 0.15. The firm has a 50 day moving average of C$0.07 and a 200-day moving average of C$0.06.
Hemostemix Company Profile
Hemostemix Inc, a clinical stage biotechnology company, develops, manufactures, and commercializes blood-derived stem cell therapies for medical conditions. The company develops cell therapy products from the patient's own blood, which is a non-invasive source of therapeutic cells. Its lead product is ACP-01, an autologous cell therapy, which is in Phase II clinical trial for the treatment of vascular diseases, such as cardiovascular disease, peripheral arterial disease, angina pectoris, and ischemia in Canada and the United States.
Featured Stories
- Five stocks we like better than Hemostemix
- How Can Retail Investors Trade the Toronto Stock Exchange (TSX)?
- The Outlook for Interest Rate Cuts Got Blown Out of the Water
- Trading Stocks: RSI and Why it’s Useful
- 3 High-Risk, High-Reward Micro-Cap Stocks You Shouldn’t Ignore
- Following Congress Stock Trades
- 3 Bargain Stocks Positioned for Gains After Missing 2024’s Rally
Receive News & Ratings for Hemostemix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hemostemix and related companies with MarketBeat.com's FREE daily email newsletter.